Do you want to read an article? Please log in or register.
Approaching Clinical Trials in Childhood ILD (chILD) and Pediatric Pulmonary Fibrosis
Interstitial Lung DiseasePulmonary Fibrosis
RECOMMENDED
Related content
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Lancet Respir Med
Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW
RECOMMENDED
Pulmonary Fibrosis
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
JAMA
Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative.
doi: 10.1001/jama.2021.4956
RECOMMENDED
CoughPulmonary Fibrosis
Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
Dutta P, Funston W, Mossop H, Ryan V, Jones R, Forbes R, Sen S, Pearson J, Griffin SM, Smith JA, Ward C, Forrest IA, Simpson AJ
doi: 10.1136/thoraxjnl-2018-212102.
RECOMMENDED
Pulmonary Fibrosis
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Am J Respir Crit Care Med.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW; OPTIMIZE Study Group
doi: 10.1164/rccm.
RECOMMENDED
Further Publications
Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Scott JV, Garnett CE, Kanwar MK, Stockbridge NL, Benza RL
doi: 10.1164/rccm.202002-0357OC.
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
Pulmonary Fibrosis
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
EBioMedicine.
Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL
doi: 10.1016/j.ebiom.2018.12.052.
RECOMMENDED
Pulmonary Fibrosis
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
VanDevanter DR, Hamblett NM, Simon N, McIntosh J, Konstan MW
doi: 10.1016/j.jcf.2020.07.008.
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results
Swiss Med Wkly.
Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C
doi: 10.4414/smw.2018.14593.